Abstract

Reduction of Tau protein expression was described in 2003 by Zhukareva et al. in a variant of frontotemporal lobar degeneration (FTLD) referred to as diagnosis of dementia lacking distinctive histopathology, then re-classified as FTLD with ubiquitin inclusions. However, the analysis of Tau expression in FTLD has not been reconsidered since then. Knowledge of the molecular basis of protein aggregates and genes that are mutated in the FTLD spectrum would enable to determine whether the “Tau-less” is a separate pathological entity or if it belongs to an existing subclass of FTLD. To address this question, we have analyzed Tau expression in the frontal brain areas from control, Alzheimer’s disease and FTLD cases, including FTLD- Tau (MAPT), FTLD-TDP (sporadic, FTLD-TDP-GRN, FTLD-TDP-C9ORF72) and sporadic FTLD-FUS, using western blot and 2D-DIGE (Two-Dimensional fluorescence Difference Gel Electrophoresis) approaches. Surprisingly, we found that most of the FTLD-TDP-GRN brains are characterized by a huge reduction of Tau protein expression without any decrease in Tau mRNA levels. Interestingly, only cases affected by point mutations, rather than cases with total deletion of one GRN allele, seem to be affected by this reduction of Tau protein expression. Moreover, proteomic analysis highlighted correlations between reduced Tau protein level, synaptic impairment and massive reactive astrogliosis in these FTLD-GRN cases. Consistent with a recent study, our data also bring new insights regarding the role of progranulin in neurodegeneration by suggesting its involvement in lysosome and synaptic regulation. Together, our results demonstrate a strong association between progranulin deficiency and reduction of Tau protein expression that could lead to severe neuronal and glial dysfunctions. Our study also indicates that this FTLD-TDP-GRN subgroup could be part as a distinct entity of FTLD classification.Electronic supplementary materialThe online version of this article (doi:10.1186/s40478-016-0345-0) contains supplementary material, which is available to authorized users.

Highlights

  • Frontotemporal Lobar Degeneration (FTLD) accounts for 10 to 20 % of all demented cases

  • Reduction of Tau protein expression is observed in FTLDTDP brains associated with GRN gene mutation without Tau mRNA decrease Tau protein expression was studied in all cases

  • We first checked by western-blotting, if there was any Tau pathology in these brains, since it has been described in Alzheimer’s disease (AD), and a subset of FTLD-TDP patients [27, 28]

Read more

Summary

Introduction

Frontotemporal Lobar Degeneration (FTLD) accounts for 10 to 20 % of all demented cases. Gene mutations play an important role in FTLD with 30 to 50 % of patients reporting a positive family history of FTD and 10 to 15 % of patients corresponding to dominantly inherited form [6]. Mutations in the progranulin gene GRN were found to be the most frequent mutations associated with FTLD [8, 9]. Two studies demonstrated that expanded hexanucleotide GGGGCC repeats in a noncoding region of the chromosome 9 open reading frame 72 (C9ORF72) gene was responsible for a large proportion of both familial FTLD and ALS [10, 11]. Less frequently mutations in the valosin containing protein (VCP) gene or charged multivesicular body protein 2B (CHMP2B) gene are found associated with FTLD [12, 13]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call